Investor Overview

Stock Information
Loading data...

Shares outstanding

100,328,686 (as of 08/08/2024)

Press Releases
Nov 14, 2024

— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — —...

Nov 6, 2024

Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to...

Oct 28, 2024

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today...

Sep 20, 2024

Endometriosis Affects Approximately 190 Million Women Worldwide Non-invasive MET™ Diagnostic Test for Endometriosis Leverages Novel Biomarker: A Specific Deletion in Mitochondrial DNA...

Sep 9, 2024

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB:...

View all

Evofem Investor Presentation
Subscribe for Alerts

Company Overview

Featured Event
Monday, October 28, 2024
11:30 am EDT

Saundra Pelletier, CEO of Evofem Biosciences, joined Aditxt CEO Amro Albanna and MD and media personality Dr. Drew Pinsky for a Virtual Fireside Chat on October 28, 2024.

View All

Latest Financial Results

Q2 ended June 30, 2024

Earnings Release
10-Q Filing
XBRL